Norges Bank reduced its holdings in Pharmaron Beijing (03759) by 2.8013 million shares at a price of approximately HKD 27.23 per share.
On August 7, Norges Bank reduced its holdings in CanSino Biologics (03759) by 2,801,300 shares, at a price of HK$27.2286 per share, totaling approximately HK$76,275,500.
According to the latest data from the Hong Kong Stock Exchange, on August 7, Norges Bank reduced its holdings in Pharmaron Beijing (03759) by 2.8013 million shares, at a price of HKD 27.2286 per share, totaling approximately HKD 76.2755 million. After the reduction, the latest number of shares held is approximately 16.097 million, with the latest shareholding ratio at 4.49%.
Related Articles
In the first seven months, CHINA JINMAO (00817) accumulated a signed sales amount of 66.702 billion yuan, an increase of 7.92% year-on-year.
CNE TECH CORP (00611) issued a profit warning, expecting a mid-term net profit of no less than 30 million yuan, a decrease of no more than 65% compared to the same period last year.
CSPC PHARMA (01093): The Phase I clinical trial of SYS 6063 for the treatment of refractory relapse systemic lupus erythematosus has officially launched at the first center in China.
In the first seven months, CHINA JINMAO (00817) accumulated a signed sales amount of 66.702 billion yuan, an increase of 7.92% year-on-year.
CNE TECH CORP (00611) issued a profit warning, expecting a mid-term net profit of no less than 30 million yuan, a decrease of no more than 65% compared to the same period last year.
CSPC PHARMA (01093): The Phase I clinical trial of SYS 6063 for the treatment of refractory relapse systemic lupus erythematosus has officially launched at the first center in China.
RECOMMEND
